These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

117 related articles for article (PubMed ID: 14642627)

  • 1. Core promoter/pre-core mutations are associated with lamivudine-induced HBeAg loss in chronic hepatitis B with genotype C.
    Asahina Y; Izumi N; Uchihara M; Noguchi O; Nishimura Y; Inoue K; Ueda K; Tsuchiya K; Hamano K; Itakura J; Miyake S
    J Hepatol; 2003 Dec; 39(6):1063-9. PubMed ID: 14642627
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Genetic heterogeneity of the precore and the core promoter region of genotype C hepatitis B virus during lamivudine therapy.
    Kuwahara R; Kumashiro R; Murashima S; Ogata K; Tanaka K; Hisamochi A; Hino T; Ide T; Tanaka E; Koga Y; Sata M
    J Med Virol; 2004 Jan; 72(1):26-34. PubMed ID: 14635007
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comparison of sequence changes of precore and core promoter regions in HBeAg-positive chronic hepatitis B patients with and without HBeAg clearance in lamivudine therapy.
    Chen CH; Lee CM; Lu SN; Changchien CS; Wang JC; Wang JH; Hung CH; Hu TH
    J Hepatol; 2006 Jan; 44(1):76-82. PubMed ID: 16298013
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Evolution of hepatitis B virus polymerase gene mutations in hepatitis B e antigen-negative patients receiving lamivudine therapy.
    Lok AS; Hussain M; Cursano C; Margotti M; Gramenzi A; Grazi GL; Jovine E; Benardi M; Andreone P
    Hepatology; 2000 Nov; 32(5):1145-53. PubMed ID: 11050068
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Reversion from precore/core promoter mutants to wild-type hepatitis B virus during the course of lamivudine therapy.
    Cho SW; Hahm KB; Kim JH
    Hepatology; 2000 Nov; 32(5):1163-9. PubMed ID: 11050070
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effects of interferon alpha therapy on the catalytic domains of the polymerase gene and basal core promoter, precore and core regions of hepatitis B virus.
    Chen RY; Bowden S; Desmond PV; Dean J; Locarnini SA
    J Gastroenterol Hepatol; 2003 Jun; 18(6):630-7. PubMed ID: 12753143
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Mutations in pre-core and basic core promoter regions of hepatitis B virus in chronic hepatitis B patients.
    Wang XL; Ren JP; Wang XQ; Wang XH; Yang SF; Xiong Y
    World J Gastroenterol; 2016 Mar; 22(11):3268-74. PubMed ID: 27004005
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Association of baseline viral factors with response to lamivudine therapy in chronic hepatitis B patients with high serum alanine aminotransferase levels.
    Tseng TC; Liu CJ; Wang CC; Chen PJ; Lai MY; Chen DS; Kao JH
    Antivir Ther; 2009; 14(2):203-10. PubMed ID: 19430095
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The clinical impact of early detection of the YMDD mutant on the outcomes of long-term lamivudine therapy in patients with chronic hepatitis B.
    Paik YH; Han KH; Hong SP; Lee HW; Lee KS; Kim SO; Shin JE; Ahn SH; Chon CY; Moon YM
    Antivir Ther; 2006; 11(4):447-55. PubMed ID: 16856618
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Association of core promoter mutations with viral breakthrough in chronic hepatitis B patients on long-term lamivudine therapy.
    Kazim SN; Chauhan R; Das BC; Sarin SK
    J Gastroenterol Hepatol; 2006 Oct; 21(10):1525-32. PubMed ID: 16928212
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Viral genotype and baseline load predict the response to adefovir treatment in lamivudine-resistant chronic hepatitis B patients.
    Buti M; Elefsiniotis I; Jardi R; Vargas V; Rodriguez-Frias F; Schapper M; Bonovas S; Esteban R
    J Hepatol; 2007 Sep; 47(3):366-72. PubMed ID: 17561304
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Efficacy of lamivudine therapy and factors associated with emergence of resistance in chronic hepatitis B virus infection in Japan.
    Suzuki F; Tsubota A; Arase Y; Suzuki Y; Akuta N; Hosaka T; Someya T; Kobayashi M; Saitoh S; Ikeda K; Kobayashi M; Matsuda M; Satoh J; Takagi K; Kumada H
    Intervirology; 2003; 46(3):182-9. PubMed ID: 12867757
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Changes in serum hepatitis B e antigen (HBeAg) levels associated with the emergence of YMDD mutants in HBeAg non-seroconverted patients during lamivudine therapy.
    Yen YH; Lu SN; Chen CH; Wang JH; Wu CM; Hung CH; Tseng PL; Hu TH; Changchien CS; Lee CM
    Liver Int; 2007 Dec; 27(10):1349-55. PubMed ID: 18036099
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Significance of viral load, core promoter/precore mutations and specific sequences of polymerase gene in HBV-infected patients on 3-year lamivudine treatment.
    Yuen MF; Sablon E; Libbrecht E; Van De Velde H; Wong DK; Fung J; Wong BC; Lai CL
    Antivir Ther; 2006; 11(6):779-86. PubMed ID: 17310822
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Presence of precore and core promoter mutants limits the probability of response to peginterferon in hepatitis B e antigen-positive chronic hepatitis B.
    Sonneveld MJ; Rijckborst V; Zeuzem S; Heathcote EJ; Simon K; Senturk H; Pas SD; Hansen BE; Janssen HL
    Hepatology; 2012 Jul; 56(1):67-75. PubMed ID: 22307831
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Clinical reactivation during lamivudine treatment correlates with mutations in the precore/core promoter and polymerase regions of hepatitis B virus in patients with anti-hepatitis B e-positive chronic hepatitis.
    Marrone A; Zampino R; Karayannis P; Cirillo G; Cesaro G; Guerrera B; Ricciotti R; del Giudice EM; Utili R; Adinolfi LE; Ruggiero G
    Aliment Pharmacol Ther; 2005 Oct; 22(8):707-14. PubMed ID: 16197491
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Impact of hepatitis B e antigen-suppressing mutations on the replication efficiency of entecavir-resistant hepatitis B virus strains.
    Amini-Bavil-Olyaee S; Herbers U; Luedde T; Trautwein C; Tacke F
    J Viral Hepat; 2011 Nov; 18(11):804-14. PubMed ID: 20887378
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Distinct evolution and predictive value of hepatitis B virus precore and basal core promoter mutations in interferon-induced hepatitis B e antigen seroconversion.
    Yang HC; Chen CL; Shen YC; Peng CY; Liu CJ; Tseng TC; Su TH; Chuang WL; Yu ML; Dai CY; Liu CH; Chen PJ; Chen DS; Kao JH
    Hepatology; 2013 Mar; 57(3):934-43. PubMed ID: 23112104
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Differences of YMDD mutational patterns, precore/core promoter mutations, serum HBV DNA levels in lamivudine-resistant hepatitis B genotypes B and C.
    Pan XP; Li LJ; Du WB; Li MW; Cao HC; Sheng JF
    J Viral Hepat; 2007 Nov; 14(11):767-74. PubMed ID: 17927612
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Clinical significance of hepatitis B virus precore and core promoter variants in Korean patients with chronic hepatitis B.
    Yim SY; Um SH; Young Jung J; Kim TH; Kim JD; Keum B; Seo YS; Yim HJ; Jeen YT; Lee HS; Chun HJ; Kim CD; Ryu HS
    J Clin Gastroenterol; 2015 Jan; 49(1):61-8. PubMed ID: 24406435
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.